SLC5A2 and hydrops fetalis: Currently, several ongoing clinical studies are evaluating the effects of SGLT2inhibitors on biomarkers, health status, functional status and diastolic functionin patients with HFpEF, making the prospect of further understanding themechanisms behind the cardiovascular benefit of SGLT2 inhibition an exciting timefor HF research, with the potential to establish new frontiers in HFpEFmanagement.